Table 3 |
||||||
|
Comparison of baseline characteristics and antipyretic treatments of survivors and non-survivors |
||||||
|
Patients with sepsis |
Patients without sepsis |
|||||
|
|
||||||
|
Survivors (N = 471) |
Non-survivors (N = 135) |
P-value |
Survivors (N = 783) |
Non-survivors (N = 36) |
P-value |
|
|
|
||||||
|
Gender (male) n (%) |
291 (61.8%) |
94 (69.6%) |
0.10 |
485 (61.9%) |
23 (63.9%) |
0.81 |
|
Age (y.o., IQR) |
67 (54, 75) |
69 (58, 78) |
0.08 |
64 (54, 73) |
74.5 (59, 81.5) |
0.003 |
|
APACHE (IQR) |
20 (16, 24) |
24 (21, 28) |
< 0.001 |
13 (10, 18) |
24 (19.5, 28) |
< 0.001 |
|
Postoperative admission n (%) |
59 (12.5%) |
9 (6.7%) |
0.057 |
523 (66.8%) |
11 (30.6%) |
< 0.001 |
|
Mechanical ventilation requirement n (%) |
317 (67.3%) |
112 (83.0%) |
< 0.001 |
498 (63.6%) |
30 (83.3%) |
0.016 |
|
Reasons for admission n (%) |
||||||
|
Cardiac or vascular diseases |
93 (19.7%) |
16 (11.9%) |
0.04 |
422 (53.9%) |
13 (36.1%) |
0.04 |
|
Thoracic or respiratory diseases |
253 (53.7%) |
90 (66.7%) |
0.007 |
193 (24.6%) |
12 (33.3%) |
0.24 |
|
Renal or metabolic disease |
48 (10.2%) |
13 (9.6%) |
0.85 |
51 (6.5%) |
3 (8.3%) |
0.67 |
|
Gastrointestinal tract diseases |
56 (11.9%) |
12 (8.9%) |
0.33 |
102 (13%) |
6 (16.7%) |
0.53 |
|
Other |
21 (4.5%) |
4 (3%) |
0.44 |
15 (1.9%) |
2 (5.6%) |
0.13 |
|
Length of stay in ICU |
8 (5, 14) |
9 (5, 15) |
0.74 |
5 (4, 7) |
5 (4, 9) |
0.11 |
|
|
||||||
|
NSAIDs |
||||||
|
Number of patients n (%) (Un adjusted odds ratio (95% CI)) |
19 (4%) |
12 (8.9%) |
0.02 |
98 (12.5%) |
1 (2.8%) |
0.08 |
|
(2.32 (1.10, 4.91)) |
(0.20 (0.03, 1.47)) |
|||||
|
Delta body temperature* (°C, IQR) |
-0.4 (-0.9, -0.1) |
-0.1 (-0.6, 0.0) |
0.08 |
-0.4 (-0.7, 0) |
0.0 (0.0, 0.0) |
0.30 |
|
|
||||||
|
Acetaminophen n (%) |
||||||
|
Number of patients n (%) (Un adjusted odds ratio (95%CI)) |
75 (15.9%) |
41 (30.4%) |
0.002 |
31 (4%) |
1 (2.8%) |
0.72 |
|
(2.30 (1.48, 3.58)) |
(0.69 (0.09, 5.23)) |
|||||
|
Delta body temperature* (°C, IQR) |
-0.4 (-1.1, -0.1) |
-0.4 (-0.9, -0.2) |
0.94 |
-0.3 (-0.7, 0.0) |
-0.9 (-0.9, -0.9) |
0.28 |
|
|
||||||
|
Cooling n (%) |
||||||
|
Number of patients n (%) (Unadjusted odds ratio (95%CI)) |
223 (47.3%) |
64 (47.4%) |
0.99 |
366 (46.7%) |
18 (50%) |
0.74 |
|
(1.00 (0.68, 1.46)) |
(1.14 (0.58, 2.22)) |
|||||
|
Delta body temperature* (°C, IQR) |
-0.2 (-0.4, 0) |
-0.2 (-0.5, 0) |
0.55 |
-0.1 (-0.3, 0) |
-0.1 (-0.4, 0) |
0.16 |
|
|
||||||
|
APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidential interval; IQR, 25%, 75% interquartile; NSAIDs, non-steroid anti-inflammatory drugs *, Delta body temperature from application of antipyretic to next temperature monitoring |
||||||
|
Fever and Antipyretic in Critically ill patients Evaluation (FACE) Study Group et al. Critical Care 2012 16:R33 doi:10.1186/cc11211 |
||||||
